Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Front Public Health. 2023 Jan 25;10:984810. doi: 10.3389/fpubh.2022.984810. eCollection 2022.
Because of insidious progression and no significant clinical symptoms at early stage, chronic hepatitis C (CHC) is often diagnosed after the occurrence of cirrhosis and hepatocellular carcinoma. Highly effective and low drug resistance of direct-acting antiviral agents (DAAs) have enabled cure of CHC, encouraging the World Health Organization to propose a global viral hepatitis elimination program. To Date, vaccine for CHC is still under research. Therefore, reducing the source of infection is an important means of eliminating CHC other than cutting off the transmission route, which requires screening, diagnosing and treating as many patients in the population as possible. Hospital-based screening strategy have been found to be cost-effective in the management of CHC screening, as reported both nationally and internationally. Currently, China has issued in April, 2021, which provides a standardized implementation process and direction for in-hospital hepatitis C screening and treatment, but still requires medical institution to develop its own management process, taking into account its current situation and learning from domestic and international experience. In addition, screening for CHC outside the hospital among special populations, such as blood donors, pregnant women, homosexuals, intravenous drug users, prisoners, and residents in rural areas with scarce medical care resources, also requires attention and development of targeted and rational screening strategies. In this paper, we analyze and recommend the management of hepatitis C screening from both in-hospital and out-of-hospital perspectives, with the aim of contributing to the formulation of hepatitis C screening strategies.
由于慢性丙型肝炎(CHC)在早期阶段进展隐匿且无明显临床症状,因此常在发生肝硬化和肝细胞癌后才被诊断。直接作用抗病毒药物(DAAs)的高效低耐药性使得 CHC 得以治愈,这促使世界卫生组织提出了全球病毒性肝炎消除计划。迄今为止,CHC 疫苗仍在研究中。因此,减少感染源是消除 CHC 的重要手段之一,除了切断传播途径外,还需要尽可能对人群中的更多患者进行筛查、诊断和治疗。国内外的研究均表明,基于医院的筛查策略在 CHC 筛查管理中具有成本效益。目前,中国已于 2021 年 4 月发布了相关指南,为院内 CHC 筛查和治疗提供了标准化的实施流程和方向,但仍需要医疗机构根据自身情况制定管理流程,并借鉴国内外经验。此外,还需要关注和制定针对特殊人群(如献血者、孕妇、同性恋者、静脉吸毒者、囚犯和医疗资源匮乏的农村居民)的院外 CHC 筛查策略。本文从院内和院外两个角度分析并推荐 CHC 筛查管理,以期为 CHC 筛查策略的制定提供参考。